| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE SODIUM | 101 |
| 1 | METHOTREXATE | 78 |
| 2 | PREDNISONE | 50 |
| 3 | CYCLOPHOSPHAMIDE | 42 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 42 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 42 |
| 6 | ROMIDEPSIN | 40 |
| 7 | ADALIMUMAB | 37 |
| 8 | BRENTUXIMAB VEDOTIN | 35 |
| 9 | PREDNISOLONE | 34 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ROMIDEPSIN | 40 | 0.0237 |
| 1 | BRENTUXIMAB VEDOTIN | 35 | 0.0034 |
| 2 | PRALATREXATE | 2 | 0.0031 |
| 3 | PALIFERMIN | 1 | 0.0026 |
| 4 | CIDOFOVIR ANHYDROUS | 3 | 0.0021 |
| 5 | PROBENECID | 2 | 0.0017 |
| 6 | SODIUM HYALURONATE | 1 | 0.0012 |
| 7 | DUVELISIB | 1 | 0.0012 |
| 8 | ACYCLOVIR SODIUM | 1 | 0.0008 |
| 9 | HYDROCORTISONE SODIUM SUCCINATE | 3 | 0.0008 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 4 | 0.0058 |
| 1 | CD30-directed Immunoconjugate [EPC] | 35 | 0.0034 |
| 2 | Mucocutaneous Epithelial Cell Growth Factor [EPC] | 1 | 0.0026 |
| 3 | Histone Deacetylase Inhibitor [EPC] | 4 | 0.0010 |
| 4 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 5 | Erythroid Maturation Agent [EPC] | 1 | 0.0004 |
| 6 | CD19-directed Chimeric Antigen Receptor [EPC] | 3 | 0.0003 |
| 7 | Interleukin-17A Antagonist [EPC] | 11 | 0.0003 |
| 8 | Interleukin-23 Antagonist [EPC] | 25 | 0.0002 |
| 9 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 5 | 0.0002 |